红人归胶囊治疗更年期综合征作用机制初探

目的进行红人归胶囊(HRG)治疗更年期综合征机制的研究。方法采用去势雌性(ovariec-tomized,OVX)大鼠作为更年期动物模型,放射性免疫法测定OVX大鼠血清雌二醇含量,高效液相色谱-电化学检测法测定下丘脑单胺神经递质及其代谢产物的含量,并测定其免疫器官的脏器系数。结果HRG可使OVX大鼠血清雌二醇含量升高,使下丘脑升高的5-羟色胺(5-HT)及其代谢产物5-羟色胺酸(5-HIAA)含量明显下降,显著提高去甲肾上腺素(NE)和多巴胺(DA)含量,使升高的5-HT含量与NE含量的比值降低至接近正常;HRG能提高OVX大鼠胸腺系数和脾系数。结论HRG通过调节植物神经功能、生殖内分泌系统和免疫功能,多层次、多途径、多环节地作用于更年期衰退的神经内分泌免疫网络,从而起到稳定机体内环境,缓解更年期症状的作用。     

Anti-osteoporosis effect of the standard extract of Pueraria Lobata

Objective The standard extract of Pueraria Lobata(SEP)was extracted from the traditional Chinese medicine Pueraria Lobata.and the anti-osteoporotic effect of SEP were evaluated in the paper.Methods The ovariotomied rats were used simulating osteoporosis model,and characterized from thighbone measurement,bone density,blood biochemistry assay,emiction biochemistry,bone morphology and womb pathology were also determined.Results The ovariotomy causes rats' weight,serum ALP,Strap,bone calcium element,emiction calcium element,emiction hydroxide praline increased;bone calcium content,bone density and rigidity,thighbone wet weight,dry weight and ash weight remarkably reduced;and the bone anti-bend intensity,the maximum bend strength decreased,the bone girder thinner,or even be broken.This indicates that ovariotomy causes rats lost bone calcium and got osteoporosis.One month after operation,SEP was provided subsequently for 12 weeks to different samples(medicament quantity 2.5,1.25,0.625 g·kg-1;model group;fake operational group and masculine medicament estrogen group).It was found that SEP can suppress the weight increase caused by ovariotomy,improved the thighbone metrology standard of the OVX rats(the bone calcium content 26.2%,20.1% and 15.7% separately);increase the thighbone density and rigidity,the thighbone wet weight,dry weight and ash weight;increased blood calcium,blood phosphorus,decreasing ALP,Strap,increasing serum estradiol level,reducing bone calcium content;improve the emiction biochemistry characteristics:decreased emiction calcium,emiction hydroxide proline ejection amount;improved the OVX rats thighbone biomechanics characteristic:increased the anti-band intensity and maximum bend strength.Conclusions SEP exerted upon an inhibited effects on osteoporosis caused by ovariotomy.     

黄柏小檗碱对去卵巢大鼠骨质疏松症的作用

目的：研究黄柏小檗碱对去卵巢大鼠骨质疏松症的作用.方法：去卵巢以建立大鼠骨质疏松症模型,将大鼠随机分为假手术组、去卵巢组,尼尔雌醇组及低（10 mg/kg）、中（30 mg/kg）、高（90 mg/kg）剂量黄柏小檗碱组进行实验,每组10只.12周后,以比色法测定其血清钙、磷的浓度和碱性磷酸酶的活性,竞争放射免疫法测定血清中骨钙素、降钙素、甲状旁腺素及雌二醇的浓度;双能X射线骨密度仪测定大鼠股骨干骺端的骨密度.结果：黄柏小檗碱能够增加去卵巢大鼠子宫重量、股骨干骺端的骨密度和血清无机磷含量;降低碱性磷酸酶活性和甲状旁腺素浓度,增加血清雌二醇、骨钙素、降钙素浓度.结论：黄柏小檗碱对去卵巢大鼠骨质疏松症具有防治作用,其机制可能是抑制骨吸收、促进骨形成,促进雌二醇和降钙素合成.     

益骨胶囊对骨质疏松模型大鼠骨形态学及血清TNF-α水平的影响

目的:观察益骨胶囊对骨质疏松(OP)模型大鼠形态学及血清肿瘤坏死因子(TNF -α)水平的影响。方法:将大鼠分为假手术组、模型组和治疗组,模型组和治疗组大鼠切除双侧卵巢建立OP模型,之后测定各组骨密度;取骨组织脱钙切片观察骨形态学;采用放射免疫法测定血清E2 和TNF -α水平。结果:与假手术组比较,模型组骨密度及血清E2 水平降低,血清TNF -α水平升高(P<0. 01) ;与模型组比较,治疗组骨形态明显改善,骨密度及血清E2 水平增加,血清TNF -α水平降低(P<0 .05或P<0. 01) ,与假手术组接近。结论:益骨胶囊能有效改善OP模型大鼠的骨质疏松状况。     

XW630对去卵巢大鼠骨质疏松的作用(英文)

目的:研究XW630对去卵巢大鼠骨质疏松的影响。方法:血清E_2和骨钙素(BGP)浓度用放射免疫测定法。骨组织计量学用四环素内标法。结果:去卵巢后,血清E_2水平下降61.9％,子宫减轻72.7％,动情次数减少63.6％。XW630治疗13周后,血清BGP浓度增加75.7％,动情次数略增加,但低于假手术组,血清E_2浓度及子宫重量无明显变化。与OVX组相比,XW630组骨组织计量学指标TBV/TTV,TBV/SBV和MTPD增加;Sfract(s),Sfract(d),TOS和Svf增加,OMP缩短。结论:XW630增加骨激活频率、骨小梁连接性、稳定性和张力。表明XW630促进骨形成、抑制骨吸收,对生殖系统无影响。     

Isolation and identification of steroidogenic peptides from calf spleen

Since women with climacteric syndrome have significantly lower serum levels of estradiol and other related hormones, hormone replacement therapies (HRT) such as estrogen are needed to lessen symptoms. However, HRT can often cause severe adverse effects that include many cancers and stroke. Therefore, new and novel approaches to relieve climacteric syndrome still need to be developed. The aim of this study was to identify biologically active peptides from calf spleen that are responsible for stimulating biosynthesis of steroid hormone and to explore the potential of isolated peptides as therapeutic agents for menopausal syndrome. The reverse phase HPLC system was used to isolate active compounds from calf spleen extract, a cell culture system was used to screen the activity of stimulating hormone secretion, and Matrix-Assisted Laser Desorption/Ionization (MALDI) mass spectrometry was used for molecular weight determination. In the present study, two calf steroidogenic peptides, CSP-1 (MW; 4.655 kDa) and CSP-2 (MW; 8.331 kDa), were isolated and identified from calf spleen and may be putative climacteric syndrome therapeutic agents.     

Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain.

Hormonal specificity of modulation of brain 5-HT(2A) receptors was investigated by comparing activity of compounds with varying effects on estrogen response in breast, bone, and uterus. A two-week estradiol treatment stimulated the decreased uterine weight of ovariectomized rats to intact rat values whereas an increase of 29% with tamoxifen and 16% with raloxifene was observed compared to vehicle-treated ovariectomized rats. In 18 assayed brain regions, ovariectomy decreased 5-HT(2A) receptor binding and mRNA levels in anterior cingulate and frontal cortices, striatum, and nucleus accumbens; estradiol restored this decrease to intact rat values. Dehydroepiandrosterone (DHEA) increased ovariectomized rats 5-HT(2A) receptor expression only in striatum and cortical amygdala. Tamoxifen increased 5-HT(2A) receptor density only in striatum. Raloxifene, an uterine estrogen receptor (ER) antagonist, increased, like estradiol, 5-HT(2A) receptor density and expression in cingulate and frontal cortices, striatum, and nucleus accumbens. Brain regional specificity of estradiol, DHEA, tamoxifen, and raloxifene on 5-HT(2A) receptors was observed which can be dissociated from peripheral activity.     

力骨胶囊防治大鼠实验性骨质疏松症的药效学

目的研究力骨胶囊预防和治疗维甲酸致大鼠骨质疏松症的药效学。方法采用维甲酸致大鼠实验性骨质疏松模型 ,随机分组给药 ,检测实验鼠股骨密度、断裂载荷、湿重、干重等物理指标及相关生化指标。结果力骨胶囊能明显提高模型大鼠的股骨密度和断裂载荷 ,显著增加模型大鼠血清Ca、P、Mg水平 ,降低模型大鼠血清ALP水平及羟脯氨酸与肌酐比值 ,并增加模型大鼠的股骨湿重、干重、灰重、体积、长度、直径等。结论力骨胶囊可有效地预防和治疗维甲酸诱导的大鼠实验性骨质疏松     

Calcium-level responsive controlled drug delivery from implant dosage forms to treat osteoporosis in an animal model

The effects of plasma calcium levels on estradiol release from a self-setting apatite bone cement containing 0.5% estradiol and on the bone mineral density (BMD) of ovariectomized rats were investigated. Apatite cement consisting of an equimolar mixture of tetracalcium phosphate, dicalcium phosphate dihydrate and 0.5% beta-estradiol was prepared. The in vitro release profiles from the cements in simulated body fluid containing 0, 5 and 10 mg/100 ml calcium indicated that estradiol release rate decreased with increasing calcium concentration in the dissolution medium. After subcutaneous implantation of the cement, in vivo estradiol release in diseased rats (ovariectomized rats on a low calcium diet) was significantly higher than that in normal rats. The diseased rats maintained a low calcium level during drug release. The bone mass of the recovery model rat was greater after the experiment than before. The results suggested that the severity of osteoporosis in this animals can be reduced by the implantation of this estradiol-loaded apatite cement.     

Effect of Bixieqianggupian on experimental osteoporosis in rats

Objective To search the effects of Bixieqianggupian(BXQBP)on osteoporosis.Methods The experimental models of osteoporosis(OP)induced by ovariectomy(OVX),retinoic acid(RA)and dexamethasone(DXM)in rats were introduced in this study.In the same time,the influence on tibia fracture healing in rats was also observed.Moreover,the anti-inflammation effects and analgesia of BXQBP in mice and rats were also studied.Results The body weight gain induced by OVX was prevented obviously by administering BXQBP.And serum estradiol and bone gla protein(BGP)were examined by RIA,and results showed that estradiol increased and BGP decreased.Bone mineral density(BMD),bone mineral content(BMC)and bone mass of femur had increased,moreover,calcium content of bone(monitored by atomic absorption)had been improved significantly after BXQBP administration.Furthermore,biomechanical characters of bone were measured by three point bending test,and the anti-bend intensity and maximum bend strength increased remarkably.The alkaline phosphatese(ALP)decreased.And amount of urine calcium(Ca)and hydroxyproline(HOP)decreased obviously.However,effect on the proliferation of endometria was not obvious.The RA induced OP model.Compared with model,the BMD and BMC increased markedly in BXQBP rats(i.g.30 days).And bone mass and calcium content were increased.Then BGP and ALP decreased by administering BXQBP.The anti-band intensity and maximum bend strength increased evidently.And ejection of urine Ca and HOP decreased obviously.The bone trabecula became thinner,and arranged in disorder in OP rats,however,the status was reversed obviously by administrating BXQBP.The OP model also induced by DXM in rats:Effect against weight losing caused by DXM was observed in groups of three doses(i.g.12 weeks)of BXQBP.And BMD,BMC,bone mass and calcium content increased evidently.The results showed that the fracture healing had been enhanced obviously at three doses(i.g.40 days),callus growth was promoted and bone rigidity was reinforced.Moreover,BXQBP had the anti-inflammation and analgesia effects in mice and rats.Conclusions These results indicated that BXQBP had an obviously protective effect on osteoporosis in experimental animals,and promoted the fracture healing.     

坤泰胶囊治疗妇女更年期综合征的临床研究

目的:评价中成药坤泰胶囊治疗更年期综合征疗效以及卵巢功能状态对其影响.方法:采用两中心随机、双盲、双模拟平行对照研究3个月,共入组147例,完成123例.每日潮热3次以上的更年期妇女随机分为试验组(坤泰胶囊4粒,tid,n=77)和对照组(戊酸雌二醇片0.5 mg,qd,n=70),按照停经时间再分为绝经过渡期和绝经后2个亚组.用药时间为3个月.研究期间患者记录症状、阴道出血、乳胀等,随访时进行改良Kupperman症状(K)评分评估更年期症状,检测血清雌二醇(E2)、阴道脱落细胞评估治疗反应.结果:治疗3个月时,试验组和对照组K评分临床有效率分别为86.2%和78.9%,潮热评分有效率分别为92.3%和96.5%,两组之间均无显著性差异(P＞0.05).试验组过渡期亚组K评分临床有效率高于对照组,分别为96.5%和71.4%(P＜0.05).治疗3个月时试验组绝经过渡期亚组的E2水平和阴道上皮细胞成熟指数显著增加(P＜0.01,P＜0.05),但增加程度低于对照组.两组均无严重不良反应.结论:坤泰胶囊对改善更年期综合征症状有效,绝经过渡期卵巢尚存有一定功能时效更佳.安全性好,无严重不良反应.     

17-β-雌二醇治疗更年期综合征

目的 :评估 17 β 雌二醇治疗更年期综合征的疗效。方法 :84例患有更年期综合征的妇女分 2组 ,试验组 33例 ,年龄 4 8a±s5a ,服用 17 β 雌二醇1mg ,po ,qd ,共 3个周期 ,对照组 5 1例 ,年龄 4 8a±5a ,服用共轭雌激素 0 .62 5mg ,ро ,qd ,共 3个周期 ,2组每周期d 15均加用醋酸甲羟孕酮 4mg ,ро ,qd× 14d ,更年期综合征以改良Kupperman评分评估 ,治疗前后检查血雌二醇、促卵泡激素。结果 :治疗 3个周期后 ,2组Kupperman评分分别下降87% ,80 % ,雌二醇上升至卵泡中期水平 ,促卵泡激素显著下降 ,2组比较差异无显著意义 (P >0 .0 5 )。结论 :17 β 雌二醇治疗更年期综合征与共轭雌激素疗效相似。     

Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.

The focus of this review is hormone replacement therapy (HRT) with continuous administration of micronised, oral 17beta-estradiol 1 mg/day (herein referred to as continuous estradiol) plus micronised, oral norgestimate 90 microg/day administered for 3 days then withdrawn for 3 days in a 6-day repeating sequence (herein referred to as intermittent norgestimate). According to data from randomised, comparative trials of 1 year's duration, continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day relieves climacteric symptoms (vasomotor symptoms and vulvovaginal atrophy) in postmenopausal women. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day appeared as effective as estradiol 1 mg/day alone or continuous estradiol 2 mg/day plus continuous norethisterone acetate 1 mg/day in the treatment of postmenopausal women with vasomotor symptoms. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day was as effective as continuous estradiol 1 mg/day in causing the maturation of vaginal epithelial cells. In a randomised, double-blind study, bone mineral density (BMD) increased to a significantly greater extent and the rate of bone turnover was slower in postmenopausal women treated with continuous oral estradiol 1 mg/day plus intermittent norgestimate 90 microg/day than in placebo-treated patients. Two randomised, double-blind studies indicated that the addition of norgestimate 90 microg/day to continuous estradiol 1 mg/day did not attenuate the beneficial effects of estradiol on lipid parameters. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day was associated with increases in mean serum high density lipoprotein (HDL)-cholesterol levels and decreases in total cholesterol, low density lipoprotein (LDL)-cholesterol and lipoprotein (a) levels, compared with baseline. There was no statistically significant increase in triglyceride levels. In comparative trials, continuous oral estradiol 1 mg/day plus intermittent oral norgestimate 90 microg/day was well tolerated. Headache, breast pain or discomfort, abdominal pain or discomfort, uterine bleeding, dysmenorrhoea, oedema, nausea and depression were the most commonly reported adverse events. Continuous estradiol 1 mg/day plus intermittent oral norgestimate 90 microg/day was associated with a favourable uterine bleeding profile that improved over time. In a randomised trial, 80% of women were free from bleeding (irrespective of spotting) during month 12 of treatment. Norgestimate 90 microg/day was effective in protecting postmenopausal women against induction of endometrial hyperplasia by continuous estradiol 1 mg/day. In conclusion, data from a limited number of randomised studies indicate that HRT with continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day is effective in relieving climacteric symptoms, increasing BMD and slowing the rate of bone turnover in postmenopausal women. This HRT regimen is well tolerated and is associated with a similar incidence of adverse events to that reported in recipients of continuous estradiol 1 mg/day. The norgestimate component of the regimen provides good endometrial protection and is associated with a favourable bleeding profile. Long-term studies investigating the associated risk of breast cancer and thromboembolic events in recipients of continuous estradiol plus intermittent norgestimate are needed. In the meantime, continuous oral estradiol plus intermittent oral norgestimate can be regarded as an effective new option for HRT in postmenopausal women.     

Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation

Genistein, a soybean-derived isoflavone, has been shown to suppress osteoclastic bone resorption. To clarify the mechanisms underlying this action, we investigated the effects of genistein on the differentiation, cytoskeleton and function in mice osteoclasts in vitro and bone metabolism in ovariectomized rats. Study design: Primary OCs were isolated from 3 week-old mice and induced by 1,25(OH)(2)D(3). Then OCs were exposed to genistein at various concentration of 0 M, 10(-9) M, 10(-8) M, 10(-7) M, 10(-6) M, and 10(-5) M. The number of TRAP+ cells were counted as well as the surface area of bone resorption on bone slice. F-actin change was observed by Confocal. In vivo, forty 12 week-old female SD rats were randomly assigned to four groups: (1) sham operated (Sham); (2) (OVX); (3) ovariectomized and treated with estradiol (OVX-E); (4) ovariectomized and received genistein (OVX-G). After 12 weeks, BMD, body weight, serum level of alkaline phosphatase (ALP), acid phosphatase (ACP), osteocalcin (OC), IL-1beta, TNFalpha, IL-6 and calcitonin (CT) were evaluated. Femur were sectioned. In addition, the serum estradiol, the weight of uteri and histological behavior were also examined to indicate the side effect of genistein to the uteri. Results: In vitro, the number of TRAP+ cells decreased depending on the concentration of genistein as well as the area of bone resorption. F-actin became disorder under Confocal. In vivo, after treated with genistein, BMD and the serum level of ALP, ACP, osteocalcin increased significantly, while the serum level of IL-1beta and TNFalpha decreased. Especially, the increase of ALP and osteocalcin of OVX-G was higher than that of OVX-E. Histologically, the pachy-trabecula were observed as well as the more mineral deposition lines. Additionally, the uterus weight index and the serum estradiol in OVX-G rats were lower significantly than those of OVX-E. The epithelia of uteri gland in OVX-G appeared cubic while those of OVX-E became squamous. Conclusions: Genistein can prevent bone resorption diseases by the promotion of bone formation and the prevention of bone resorption with slight side effect.     

黄芪多糖保护去卵巢大鼠成骨细胞功能活性的机制研究

目的　探讨黄芪多糖对去卵巢大鼠成骨细胞功能活性和核因子E2相关因子（Nrf2）/血红素氧合酶-1（HO-1）/醌氧化还原酶1（NQO1）通路的影响。方法　双侧卵巢切除法构建骨质疏松大鼠模型并分为模型组、雌二醇（0.1 mg/kg）组、黄芪多糖组（20 mg/kg）、黄芪多糖（20 mg/kg）+全反式维甲酸（ARTA,7 mg/kg）组,另选健康大鼠作为假手术组（生理盐水灌胃）,每组15只,干预8周。采用X线小动物骨密度仪检测大鼠胫骨骨密度、骨矿量,三点弯曲法测定生物力学性质;分离各组大鼠骨髓间充质干细胞（BMSCs）并诱导成骨细胞分化,MTT法检测成骨细胞活性,Bradford法检测碱性磷酸酶（ALP）活性,邻甲酚酞络合酮法测定钙沉积量,酶联免疫吸附试验检测骨成型蛋白2（BMP2）、骨钙素（BGP）、骨保护素（OPG）、超氧化物歧化酶（SOD）、丙二醛（MDA）水平,Western blot检测Nrf2、HO-1和NQO1表达。结果　与假手术组相比,模型组骨密度、骨矿量、最大载量、断裂能、成骨细胞活性、ALP活性、钙沉积量和BMP2、BGP、OPG、SOD、Nrf2、HO-1、NQO1水平降低,MDA水平升高（P＜0.05）;与模型组比较,雌二醇组、黄芪多糖组大鼠骨密度、骨矿量、最大载量、断裂能、成骨细胞活性、ALP活性、钙沉积量及BMP2、BGP、OPG、SOD、Nrf2、HO-1、NQO1水平均升高,MDA水平降低（P＜0.05）,而与黄芪多糖组比较,黄芪多糖+ARTA组大鼠上述指标变化趋势相反（P＜0.05）。结论　黄芪多糖可改善去卵巢大鼠成骨细胞功能,机制可能与激活Nrf2/HO-1/NQO1通路有关。     

Protective effect of steroidal saponins from rhizome of Anemarrhena asphodeloides on ovariectomy-induced bone loss in rats

AIM: To investigate the protective effect of steroidal saponins from Anemarrhena asphodeloides (ATS) on ovariectomy (OVX)-induced bone loss. METHODS: Sprague-Dawley rats were divided into sham and OVX groups. The OVX rats were treated with vehicle, nylestriol or steroidal saponins extract for 12 weeks. Serum calcium, phosphorus, estradiol (E(2)), osteocalcin concentration and serum alkaline phosphatase activity were measured. Bone density was assayed by dual-energy X-ray absorptiometry. The undecalcified longitudinal proximal tibial metaphysical (PTM) sections were cut and stained for histomorphometric analysis of the bone. RESULTS: In OVX rats, alkaline phosphatase activities in serum were markedly increased and concentrations of osteocalcin were decreased by ATS treatment, which had no influence on the body weight. Meanwhile, atrophy of the uterus and descent of bone mineral density (BMD) was suppressed by treatment with ATS. In addition, ATS completely corrected the decreased the concentration of calcium and E(2) in serum observed in OVX rats. Histological results showed ATS prevented decreases in trabecular thickness and increases in trabecular separation of proximal tibia metaphysis (PTM) in OVX rats. However, it did not alter osteoclast number in OVX rats. Moreover, ATS (300 mg/kg) had a remarkable effect on promoting bone formation action in OVX rats. Nylestriol treatment decreased the bone formation rate and mineral apposition rate. CONCLUSION: An adequate supply of steroidal saponins of Anemarrhena asphodeloides prevented OVX-induced bone loss in rats through the promotion of bone formation but not the inhibition of bone resorption.     

复方紫归胶囊对去势大鼠血液流变学的影响

目的 :探讨复方紫归胶囊对更年期综合征大鼠的防治作用 ,为临床应用提供理论依据。方法 :采用去势大鼠作为更年期综合征动物模型 ,观察复方紫归胶囊对去势大鼠血液流变学的影响。结果 :复方紫归胶囊对去势大鼠血液流变学的全血粘度、血浆粘度、全血还原粘度和红细胞刚性指数均显著降低 ,并能降低血小板粘附率。结论 :复方紫归胶囊对更年期综合征大鼠的防治作用明显     

Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats

To evaluate the effects of a traditional Chinese herbal medicine, Hochu-ekki-to [Bu-zong-yi-qi-tang], on the bone loss induced by ovariectomy in rats, ovariectomized female rats of the Sprague-Dawley strain at age 35 weeks were daily given Hochu-ekki-to and/or 17 alpha-ethynylestradiol for 8 weeks by gastric tube and, subsequently, the serum hormone levels and the tibial bone mineral density were measured. Hochu-ekki-to treatment suppressed the ovariectomy-induced reduction of the bone mineral density in the whole and metaphysis of tibia with a slight increase of serum levels of estradiol and progesterone, maintaining bone mineral density values similar to that in the estradiol treated ovariectomized rats, as well as the intact control rats. Hochu-ekki-to is suggested to elevate the serum levels of ovarian hormones slightly and prevent bone loss in ovariectomized rats.     

藏药色珠治疗更年期综合征的实验研究

目的观察藏药色珠的乙醇浸膏对去卵巢大鼠激素的影响。方法采用雌性大鼠双侧卵巢切除模型模拟妇女更年期内分泌状态，于手术后7d开始给药，持续4周。结果藏药色珠能增加去卵巢大鼠雌二醇水平，降低卵泡刺激素和黄体生成素水平，与模型组相比有显著性差异（P〈0．05），并可改善子宫形态。结论藏药色珠能从多环节调节生殖内分泌功能。     

Morphometric analysis of osteosclerotic bone resulting from hexachlorobenzene exposure

Hexachlorobenzene (HCB) exposure has been shown to induce hyperparathyroidism and osteosclerosis in rats. Experiments were undertaken to investigate the effects of HCB-induced hyperparathyroidism and osteosclerosis on femur morphometry as well as femur breaking strength. Fischer 344 rats were dosed 5 d/wk for 15 wk with 0, 0.1, 1, 10, or 25 mg HCB/kg body weight. Hyperparathyroidism was produced in the two higher dose groups as reported previously (Andrews et al., 1989). Femur weight was significantly increased in the rats receiving 0.1, 1, and 25 mg HCB/kg body weight, whereas density was increased significantly at 1, 10, and 25 mg HCB/kg dose levels. Bone strength was also significantly increased at the three higher dose levels. Cross-sectional area of the midpoint of the femur was significantly increased at the 1 mg/kg HCB dose level. Cortical area and the proportion of the total area of the bone that the cortex occupied were significantly increased at the three higher dose levels. Medullary cavity area was significantly increased at the 0.1 mg/kg dose level but significantly decreased at the 2 higher dose levels of HCB. The right femur was significantly predominant to the left femur in weight, volume, and density through all dosing regimens. HCB exposure significantly altered bone morphometry and strength characteristics in the Fischer 344 rat.